Nanoparticle-delivered quercetin for cancer therapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 14, Issue 6, 2014, Pages 826-832

  Men, Ke ^a   Duan, Xingmei ^a   Wei, Xia Wei ^a   Gou, Ma Ling ^a   Huang, Mei Juan ^a   Chen, Li Juan ^a   Qian, Zhi Yong ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cancer therapy; Nanoparticle; Nanotechnology; Quercetin

Indexed keywords

CHITOSAN; CYCLODEXTRIN; DOXORUBICIN; GLATIRAMER; LEUPRORELIN; LIPOSOME; MACROGOL 2000; MACROGOL 4000; NANOPARTICLE; PACLITAXEL; PHOSPHATIDYLETHANOLAMINE; POLOXAMER; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIC ACID; POLYMETHACRYLIC ACID; POLYSORBATE 80; QUERCETIN; TRASTUZUMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; DRUG CARRIER;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER PREVENTION; CANCER THERAPY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; MICELLE; MICROEMULSION; NANOEMULSION; NANOENCAPSULATION; NANOTECHNOLOGY; NEOPLASM; NONHUMAN; PARTICLE SIZE; PROSTATE CANCER; REVIEW; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; ISOLATION AND PURIFICATION; METABOLISM; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL PROLIFERATION; DRUG CARRIERS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; QUERCETIN; SIGNAL TRANSDUCTION;

EID: 84904111129     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520614666140521122932     Document Type: Review

References (76)

1. Scalbert, A.; Williamson, G., Dietary intake and bioavailability of polyphenols. J. Nutr., 2000, 130, 2073-2085.
2. Saito, K., Possible site of flavonoid synthesis in the photosynthetic apparatus. Biochem. J., 1974, 144, 431-432.
3. Salunkhe, D.K.; Jadhav, S.J.; Kadam, S.S.; Chavan, J.K., Chemical, biochemical, and biological significance of polyphenols in cereals and legumes. Crit. Rev. Food Sci. Nutr., 1982, 17, 277-305.
4. Gibellini, L.; Pinti, M.; Nasi, M.; Montagna, J.P.; De Biasi, S.; Roat, E.; Bertoncelli, L.; Cooper, E.L.; Cossarizza, A., Quercetin and cancer chemoprevention. Evid. Based Comp. Alternat. Med., 2011, 591356.
5. Vijayababu, M.R.; Arunkumar, A.; Kanagaraj, P.; Venkataraman, P.; Krishnamoorthy, G.; Arunakaran, J., Quercetin downregulates matrix metalloproteinases 2 and 9 proteins expression in prostate cancer cells (PC-3). Mol. Cell Biochem., 2006, 287, 109-116.
6. Gescher, A.; Pastorino, U.; Plummer, S.M.; Manson, M.M., Suppression of tumour development by substances derived from the diet--mechanisms and clinical implications. Br. J. Clin. Pharmacol., 1998, 45, 1-12.
7. Wei, Y.Q.; Zhao, X.; Kariya, Y.; Fukata, H.; Teshigawara, K.; Uchida, A., Induction of apoptosis by quercetin: Involvement of heat shock protein. Cancer Res., 1994, 54, 4952-4957.
8. Huang, S. L.; Hsu, C.L.; Yen, G.C., Growth inhibitory effect of quercetin on SW 872 human liposarcoma cells. Life Sci., 2006, 79, 203-209.
9. Chien, S.Y.; Wu, Y.C.; Chung, J.G.; Yang, J.S.; Lu, H.F.; Tsou, M. F.; Wood, W.G.; Kuo, S.J.; Chen, D.R., Quercetin-induced apoptosis acts through mitochondrial-and caspase-3-dependent pathways in human breast cancer MDA-MB-231 cells. Hum. Exp. Toxicol., 2009, 28, 493-503.
10. Ma, H.; Nguyen, C.; Lee, K.S.; Kahn, M., Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene, 2005, 24, 3619-3631.
11. Shan, B.E.; Wang, M.X.; Li, R.Q. Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest., 2009, 27, 604-612.
12. Lee, Y.K.; Hwang, J.T.; Kwon, D.Y.; Surh, Y.J.; Park, O.J. Induction of apoptosis by quercetin is mediated through AMPKalpha1/ASK1/p38 pathway. Cancer Lett., 2010, 292, 228-236.
13. Gupta, K.; Panda, D. Perturbation of microtubule polymerization by quercetin through tubulin binding: A novel mechanism of its antiproliferative activity. Biochemistry, 2002, 41, 13029-1338.
14. Jung, Y.H.; Heo, J.; Lee, Y.J.; Kwon, T.K.; Kim, Y.H. Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5. Life Sci., 2010, 86, 351-357.
15. Fresno Vara, J.A.; Casado, E.; De Castro, J.; Cejas, P.; Belda-Iniesta, C.; Gonzalez-Baron, M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev., 2004, 30, 193-204.
16. Chen, J. Multiple signal pathways in obesity-associated cancer. Obes. Rev., 2011, 12, 1063-1070.
17. Gulati, N.; Laudet, B.; Zohrabian, V.M.; Murali, R.; Jhanwar-Uniyal, M. The antiproliferative effect of Quercetin in cancer cellsis mediated via inhibition of the PI3K-Akt/PKB pathway. Anticancer Res., 2006, 26, 1177-1181.
18. Yuan, Z.; Long, C.; Junming, T.; Qihuan, L.; Youshun, Z. & Chan, Z. Quercetin-induced apoptosis of HL-60 cells by reducing PI3K/Akt. Mol. Biol. Rep., 2012, 39, 7785-7793.
19. Pratheeshkumar, P.; Budhraja, A.; Son, Y.O.; Wang, X.; Zhang, Z.; Ding, S.; Wang, L.; Hitron, A.; Lee, J. C.; Xu, M.; Chen, G.; Luo, J.; Shi, X. Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS One, 2012, 7, e47516.
20. Xing, N.; Chen, Y.; Mitchell, S.H.; Young, C.Y. Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis, 2001, 22, 409-14.
21. Hansen, R.K.; Oesterreich, S.; Lemieux, P.; Sarge, K.D.; Fuqua, S. A. Quercetin inhibits heat shock protein induction but not heat shock factor DNA-binding in human breast carcinoma cells. Biochem. Biophys. Res. Commun., 1997, 239, 851-856.
22. Elia, G.; Amici, C.; Rossi, A.; Santoro, M.G. Modulation of prostaglandin A1-induced thermotolerance by quercetin in human leukemic cells: Role of heat shock protein 70. Cancer Res.; 1996, 56, 210-217.
23. Koishi, M.; Hosokawa, N.; Sato, M.; Nakai, A.; Hirayoshi, K.; Hiraoka, M.; Abe, M.; Nagata, K. Quercetin, an inhibitor of heat shock protein synthesis, inhibits the acquisition of thermotolerance in a human colon carcinoma cell line. Jpn J. Cancer Res., 1992, 83, 1216-1222.
24. Boutin, J.A. Tyrosine protein kinase inhibition and cancer. Int. J. Biochem., 1994, 26, 1203-1226.
25. Ferry, D.R.; Smith, A.; Malkhandi, J.; Fyfe, D.W.; deTakats, P. G.; Anderson, D.; Baker, J.; Kerr, D.J. Phase I clinical trial of the flavonoid quercetin: Pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin. Cancer Res., 1996, 2, 659-668.
26. Baghel, S.S.; Shrivastava, N.; Baghel, R.S.; Agrawal, P.; Rajput, S. A review of quercetin: Antioxidant and anticancer properties. World J. Pharm. Pharm. Sci., 2012, 1, 146-160.
27. Tanigawa, S.; Fujii, M.; Hou, D. X. Stabilization of p53 is involved in quercetin-induced cell cycle arrest and apoptosis in HepG2 cells. Biosci. Biotechnol. Biochem., 2008, 72, 797-804.
28. Vidya Priyadarsini, R.; Senthil Murugan, R.; Maitreyi, S.; Ramalingam, K.; Karunagaran, D.; Nagini, S. The flavonoid quercetin induces cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF-kappaB inhibition. Eur. J. Pharmacol., 2010, 649, 84-91.
29. Bischoff, S.C. Quercetin: Potentials in the prevention and therapy of disease. Curr. Opin. Clin. Nutr. Metab. Care, 2008, 11, 733-740.
30. Sotoca, A. M.; Ratman, D.; Van der Saag, P.; Strom, A.; Gustafsson, J. A.; Vervoort, J.; Rietjens, I. M.; Murk, A. J. Phytoestrogen-mediated inhibition of proliferation of the human T47D breast cancer cells depends on the ERalpha/ERbeta ratio. J. Steroid. Biochem. Mol. Biol., 2008, 112, 171-178.
31. Graefe, E.U.; Derendorf, H.; Veit, M. Pharmacokinetics and bioavailability of the flavonol quercetin in humans. Int. J. Clin. Pharmacol. Ther., 1999, 37, 219-233.
32. Murakami, A.; Ashida, H.; Terao, J. Multitargeted cancer prevention by quercetin. Cancer Lett., 2008, 269, 315-325.
33. Ader, P.; Wessmann, A.; Wolffram, S. Bioavailability and metabolism of the flavonol quercetin in the pig. Free. Radic. Biol. Med.; 2000, 28, 1056-1067.
34. Oliveira, E.J.; Watson, D.G.; Grant, M. H. Metabolism of quercetin and kaempferol by rat hepatocytes and the identification of flavonoid glycosides in human plasma. Xenobiotica, 2002, 32, 279-287.
35. Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol.; 2007, 2, 751-760.
36. Singh, R.; Lillard, J.W.J.R. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol., 2009, 86, 215-223.
37. Zhang, L.; Gu, F.X.; Chan, J.M.; Wang, A.Z.; Langer, R.S.; Farokhzad, O.C. Nanoparticles in medicine: Therapeutic applications and developments. Clin. Pharmacol. Ther., 2008, 83, 761-769.
38. Northfelt, D.W.; Dezube, B.J.; Thommes, J.A.; Miller, B. J.; Fischl, M. A.; Friedman-Kien, A.; Kaplan, L. D.; Du Mond, C.; Mamelok, R.D.; Henry, D.H. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDSrelated Kaposi's sarcoma: Results of a randomized phase III clinical trial. J. Clin. Oncol., 1998, 16, 2445-2451.
39. Podhajcer, O.L.; Friedlander, M.; Graziani, Y. Effect of liposomeencapsulated quercetin on DNA synthesis, lactate production, and cyclic adenosine 3':5'-monophosphate level in Ehrlich ascites tumor cells. Cancer Res., 1980, 40, 1344-1350.
40. Wang, G.; Wang, J.J.; Yang, G.Y.; Du, S.M.; Zeng, N.; Li, D.S.; Li, R.M.; Chen, J.Y.; Feng, J.B.; Yuan, S.H.; Ye, F. Effects of quercetin nanoliposomes on C6 glioma cells through induction of type III programmed cell death. Int. J. Nanomed., 2012, 7, 271-280.
41. Wong, M.Y.; Chiu, G.N. Simultaneous liposomal delivery of quercetin and vincristine for enhanced estrogen-receptor-negative breast cancer treatment. Anticancer Drugs, 2010, 21, 401-410.
42. Wong, M.Y.; Chiu, G.N. Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model. Nanomedicine., 2011, 7, 834-840.
43. Matsumura, Y.; Hamaguchi, T.; Ura, T.; Muro, K.; Yamada, Y.; Shimada, Y.; Shirao, K.; Okusaka, T.; Ueno, H.; Ikeda, M.; Watanabe, N. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer, 2004, 91, 1775-1781.
44. Papahadjopoulos, D.; Allen, T.M.; Gabizon, A.; Mayhew, E.; Matthay, K.; Huang, S.K.; Lee, K.D.; Woodle, M.C.; Lasic, D.D.; Redemann, C.; Martin, F.J. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. U S A, 1991, 88, 11460-11464.
45. Yuan, Z.P.; Chen, L.J.; Fan, L.Y.; Tang, M.H.; Yang, G.L.; Yang, H.S.; Du, X.B.; Wang, G.Q.; Yao, W.X.; Zhao, Q.M.; Ye, B.; Wang, R.; Diao, P.; Zhang, W.; Wu, H.B.; Zhao, X.; Wei, Y.Q. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Clin. Cancer Res., 2006, 12, 3193-3199.
46. Yang, W.; Ahmed, M.; Tasawwar, B.; Levchenko, T.; Sawant, R. R.; Collins, M.; Signoretti, S.; Torchilin, V.; Goldberg, S. N. Radiofrequency ablation combined with liposomal quercetin to increase tumour destruction by modulation of heat shock protein production in a small animal model. Int. J. Hyperthermia., 2011, 27, 527-538.
47. Mandal, A.K.; Das, S.; Mitra, M.; Chakrabarti, R.N.; Chatterjee, M.; Das, N. Vesicular flavonoid in combating diethylnitrosamine induced hepatocarcinoma in rat model. J. Exp. Ther. Oncol., 2008, 7, 123-133.
48. Date, A.A.; Nagarsenker, M.S.; Patere, S.; Dhawan, V.; Gude, R. P.; Hassan, P.A.; Aswal, V.; Steiniger, F.; Thamm, J.; Fahr, A. Lecithin-based novel cationic nanocarriers (Leciplex) II: Improving therapeutic efficacy of quercetin on oral administration. Mol. Pharm., 2011, 8, 716-726.
49. Couvreur, P.; Kante, B.; Roland, M.; Speiser, P. Adsorption of antineoplastic drugs to polyalkylcyanoacrylate nanoparticles and their release in calf serum. J. Pharm. Sci., 1979, 68, 1521-1524.
50. Pimple, S.; Manjappa, A. S.; Ukawala, M.; Murthy, R. PLGA nanoparticles loaded with etoposide and quercetin dihydrate individually: in vitro cell line study to ensure advantage of combination therapy. Cancer Nanotechnology, 2012, 3, 25-36.
51. Pool, H.; Quintanar, D.; De Dios Figueroa, J.; Mano, C.M.; Bechara, J.E.H.; Godínez, L.A.; Mendoza, S. Antioxidant effects of quercetin and catechin encapsulated into PLGA nanoparticles. J. Nanomaterials, 2012, 86, 1-12.
52. Ghosh, A.; Ghosh, D.; Sarkar, S.; Mandal, A.K.; Thakur Choudhury, S.; Das, N. Anticarcinogenic activity of nanoencapsulated quercetin in combating diethylnitrosamine-induced hepatocarcinoma in rats. Eur. J. Cancer. Prev., 2012, 21, 32-41.
53. Khoei, S.; Azarian, M.; Khoee, S. Effect of hyperthermia and triblock copolymeric nanoparticles as quercetin carrier on DU145 prostate cancer cells. Curr. Nanosci., 2012, 8, 690-696.
54. Wang, Q.; Bao, Y.; Ahire, J.; Chao, Y. Co-encapsulation of biodegradable nanoparticles with silicon quantum dots and quercetin for monitored delivery. Adv. Healthc. Mater., 2013, 2, 459-466.
55. Liu, Z.; Jiao, Y.; Wang, Y.; Zhou, C.; Zhang, Z. Polysaccharidesbased nanoparticles as drug delivery systems. Adv. Drug. Deliv. Rev., 2008, 60, 1650-1662.
56. Amidi, M.; Mastrobattista, E.; Jiskoot, W.; Hennink, W.E. Chitosan-based delivery systems for protein therapeutics and antigens. Adv. Drug. Deliv. Rev., 2010, 62, 59-82.
57. Zhang, Y.; Yang, Y.; Tang, K.; Hu, X. and Zou, G. Physicochemical characterization and antioxidant activity of quercetin-loaded chitosan nanoparticles. J. App. Polym. Sci., 2008, 107, 891-897.
58. Khonkarn, R.; Mankhetkorn, S.; Hennink, W.E.; Okonogi, S. PEGOCL micelles for quercetin solubilization and inhibition of cancer cell growth. Eur. J. Pharm. Biopharm., 2011, 79, 268-275.
59. Tan, B.J.; Liu, Y.; Chang, K.L.; Lim, B.K. & Chiu, G.N. Perorally active nanomicellar formulation of quercetin in the treatment of lung cancer. Int. J. Nanomed., 2012, 7, 651-661.
60. Zhao, L.; Shi, Y.; Zou, S.; Sun, M.; Lil, L.; Zhail, G. Formulation and in vitro evaluation of quercetin loaded polymeric micelles composed of pluronic P123 and D-a-tocopheryl polyethylene glycol succinate. J. Biomed. Nanotechnol., 2011, 7, 358-365.
61. Gou, M.; Wei, X.; Men, K.; Wang, B.; Luo, F.; Zhao, X.; Wei, Y.; Qian, Z., PCL/PEG copolymeric nanoparticles: Potential nanoplatforms for anticancer agent delivery. Curr. Drug. Targets., 2011, 12, 1131-1150.
62. Gao, X.; Wang, B.; Wei, X.; Men, K.; Zheng, F.; Zhou, Y.; Zheng, Y.; Gou, M.; Huang, M.; Guo, G.; Huang, N.; Qian, Z.; Wei, Y. Anticancer effect and mechanism of polymer micelle-encapsulated quercetin on ovarian cancer. Nanoscale., 2012, 4, 7021-7030.
63. Tanaka, T.; Shiramoto, S.; Miyashita, M.; Fujishima, Y.; Kaneo, Y. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int. J. Pharm., 2004, 277, 39-61.
64. Deguchi, J.O.; Aikawa, M.; Tung, C.H.; Aikawa, E.; Kim, D.E.; Ntziachristos, V.; Weissleder, R.; Libby, P. Inflammation in atherosclerosis: Visualizing matrix metalloproteinase action in macrophages in vivo. Circulation, 2006, 114, 55-62.
65. Puoci, F.; Morelli, C.; Cirillo, G.; Curcio, M.; Parisi, O.I.; Maris, P.; Sisci, D.; Picci, N. Anticancer activity of a quercetin-based polymer towards HeLa cancer cells. Anticancer. Res., 2012, 32, 2843-2847.
66. Cirillo, G.; Vittorio, O.; Hampel, S.; Iemma, F.; Parchi, P.; Cecchini, M.; Puoci, F.; Picci, N. Quercetin nanocomposite as novel anticancer therapeutic: Improved efficiency and reduced toxicity. Eur. J. Pharm. Sci., 2013, 49, 359-365.
67. Challa, R.; Ahuja, A.; Ali, J.; Khar, R.K. Cyclodextrins in drug delivery: an updated review. AAPS Pharm.Sci.Tech., 2005, 6, 329-357.
68. Hirayama, F. and Uekama, K. Cyclodextrin-based controlled drug release system. Adv. Drug Deliv. Rev., 1999, 36, 125-141.
69. Kale, R.; Saraf, M.; Juvekar, A.; Tayade, P. Decreased B16F10 melanoma growth and impaired tumour vascularization in BDF1 mice with quercetin-cyclodextrin binary system. J. Pharm. Pharmacol., 2006, 58, 1351-1358.
70. Indap, M.; Bhosle, S.C.; Tayade, P.; Vavia, P. Evaluation of toxicity and antitumour effects of a hydroxypropyl β-cyclodextrin inclusion complex of quercetin. Ind. J. Pharm. Sci., 2002, 64, 349-353.
71. Keck, C.M.; Muller, R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm., 2006, 62, 3-16.
72. Formariz, T.P.; Chiavacci, L.A.; Sarmento, V.H.; Santilli, C.V.; Tabosa do Egito, E.S.; Oliveira, A.G. Relationship between structural features and in vitro release of doxorubicin from biocompatible anionic microemulsion. Colloids Surf. B Biointerfaces, 2007, 60, 28-35.
73. Vicentini, F.T.; Simi, T.R.; Del Ciampo, J.O.; Wolga, N.O.; Pitol, D.L.; Iyomasa, M.M.; Bentley, M.V.; Fonseca, M.J. Quercetin in w/o microemulsion: in vitro and in vivo skin penetration and efficacy against UVB-induced skin damages evaluated in vivo. Eur. J. Pharm. Biopharm., 2008, 69, 948-957.
74. Rogerio, A.P.; Dora, C.L.; Andrade, E.L.; Chaves, J.S.; Silva, L. F.; Lemos-Senna, E.; Calixto, J.B. Anti-inflammatory effect of quercetin-loaded microemulsion in the airways allergic inflammatory model in mice. Pharmacol. Res., 2010, 61, 288-297.
75. Gao, L.; Zhang, D.; Chen, M. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J. Nanoparticle Res., 2008, 10, 845-862.
76. Gao, L.; Liu, G.; Wang, X.; Liu, F.; Xu, Y.; Ma, J. Preparation of a chemically stable quercetin formulation using nanosuspension technology. Int. J. Pharm., 2011, 404, 231-237.